Research Topics
Genomes and Genes
Species | Michael F PressSummaryAffiliation: University of Southern California Country: USA Publications
| Collaborators
|
Detail Information
Publications
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancerMichael F Press
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
Clin Cancer Res 14:7861-70. 2008..Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy...
The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancerNuran Bektas
Department of Pathology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
Breast Cancer Res 10:R58. 2008..To the best of our knowledge, in the current study we present for the first time a systematic characterisation of ISG15 expression in human breast cancer and normal breast tissue both at the mRNA and protein level...- Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerationsGuido Sauter
Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
J Clin Oncol 27:1323-33. 2009..Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2-targeted therapies... - Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press
Norris Comprehensive Cancer Center, University of Southern California, CA, USA
J Clin Oncol 29:859-67. 2011..This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers... - Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III studyRichard S Finn
Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
J Clin Oncol 27:5552-8. 2009..We examined the prognostic and predictive role of HER2 ECD in a randomized trial of paclitaxel with placebo or lapatinib in women with HER2-negative or -unknown breast cancer... - A genome-wide association study of breast cancer in women of African ancestryFang Chen
Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Hum Genet 132:39-48. 2013..Identification of novel risk variants for breast cancer in women of African ancestry will demand testing of a substantially larger set of markers from stage 1 in a larger replication sample... 
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trialsMichael F Press
Women's Cancers Program, Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 89195, USA
Clin Cancer Res 11:6598-607. 2005....- Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in Richard S Finn
Geffen School of Medicine at University of California, Los Angeles, CA, USA
J Clin Oncol 27:3908-15. 2009..Published data support interactions between steroid hormone and peptide growth factor signaling. We hypothesized that molecular subgroups may exist within EGF30001 that would benefit from lapatinib... - Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancerHuiyan Ma
Division of Cancer Etiology, Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA
Cancer Epidemiol Biomarkers Prev 18:479-85. 2009.... - A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancerChristopher A Haiman
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
Nat Genet 43:1210-4. 2011..25, P = 1.1 × 10(-9)), particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10(-9)). Our results identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in multiple populations... - Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic CohortChristopher A Haiman
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
BMC Cancer 9:43. 2009.... - Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American womenVeronica Wendy Setiawan
Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Cancer Genet Cytogenet 181:16-9. 2008..18, 95% CI = 0.76-1.82, P = 0.46). Our results do not support the hypothesis that the mtDNA G10398A polymorphism is, as has previously been reported, a marker of breast cancer risk in African Americans... - A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten
Department of Medicine, University of California, Los Angeles, CA, USA
Clin Breast Cancer 9:16-22. 2009..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer... - A genome-wide scan for breast cancer risk haplotypes among African American womenChi Song
Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
PLoS ONE 8:e57298. 2013.... - Lifetime recreational exercise activity and breast cancer risk among black women and white womenLeslie Bernstein
Department of Preventive Medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
J Natl Cancer Inst 97:1671-9. 2005.... - Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimensMichael F Press
Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
J Clin Oncol 20:3095-105. 2002..To compare and evaluate HER-2/neu clinical assay methods... - A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African AmericansChristopher A Haiman
Departments of Preventive Medicine and Pathology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
Cancer Res 67:3565-8. 2007..03) and stronger in those with advanced disease (411 cases and 877 controls; OR, 2.60; 95% CI, 1.56-4.34; P = 0.0002). These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk... - Serum organochlorines and breast cancer: a case-control study among African-American womenNicole M Gatto
Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, USC Norris Comprehensive Center, 1441 Eastlake Avenue, Room 4449, Los Angeles, CA 90033, USA
Cancer Causes Control 18:29-39. 2007..This study, the largest study of African-American women to date, does not support a role of DDE and total PCBs in breast cancer risk at the levels measured... - Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African AmericansFang Chen
Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Hum Mol Genet 20:4491-503. 2011..04, P = 6.1 × 10(-5)]. In this detailed analysis of the known breast cancer risk loci, we have validated and improved upon markers of risk that better characterize their association with breast cancer in women of African ancestry... - EGFR, HER2 and VEGF pathways: validated targets for cancer treatmentMichael F Press
Department of Pathology, Keck School of Medicine, Oncology, University of Southern California Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA
Drugs 67:2045-75. 2007..The results achieved with targeted therapies to date are promising, although they illustrate the need for additional preclinical and clinical study... - Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targetingTove Olafsen
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
Protein Eng Des Sel 17:315-23. 2004..62 h) was similar. Thus, minibodies with different specificities display similar pharmacokinetics, while tumor uptake may vary depending on the antigen-antibody system... - Pathological characteristics of BRCA-associated breast cancers in HispanicsVeronica I Lagos-Jaramillo
Division of Clinical Cancer Genetics, City of Hope, Duarte, CA, 91010, USA
Breast Cancer Res Treat 130:281-9. 2011..Additional research on the molecular mechanisms involved in the loss of PR in this population is warranted as it could have important implications for the treatment and prevention of breast cancer in Hispanics... - Receptor tyrosine kinase EphB4 is a survival factor in breast cancerS Ram Kumar
Department of Pathology, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, NOR 6330, Los Angeles, CA 90033, USA
Am J Pathol 169:279-93. 2006..Our data indicate that biologically active EphB4 functions as a survival factor in breast cancer and is a novel target for therapy... - Antibody-mediated targeting of replication-competent retroviral vectorsChien-Kuo Tai
Institute for Genetic Medicine, Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Hum Gene Ther 14:789-802. 2003..Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design... - Genome-scale screen for DNA methylation-based detection markers for ovarian cancerMihaela Campan
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
PLoS ONE 6:e28141. 2011..We developed a systematic multi-step biomarker discovery and verification strategy to identify candidate DNA methylation markers for the blood-based detection of ovarian cancer... - Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus
Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 23:2534-43. 2005..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy... - Lifetime recreational exercise activity and risk of breast carcinoma in situAlpa V Patel
Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Cancer 98:2161-9. 2003..02). CONCLUSIONS: The findings of the current study suggest that exercise activity may modify the risk of BCIS, particularly among women without a family history of breast carcinoma... - Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 statusHuiyan Ma
Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA
BMC Cancer 13:225. 2013..Furthermore, it is not known whether additional consideration of p53 protein status influences black-white differences in mortality risk observed when considering subtypes defined by ER, PR and HER2 status... - Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trialLinda Hovanessian-Larsen
Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Contraception 86:238-43. 2012.... - P7 antigen expression in human breast cancerXiaowei Yang
Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA
Clin Cancer Res 9:201-6. 2003..The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome... - Identification of TP53 mutations in human cancers using oligonucleotide microarraysWen-Hsiang Wen
Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Methods Mol Med 97:323-35. 2004